Zeke Capital Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Zeke Capital Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$26.3K	Hold	49,700	–	–	﹤0.01%	468
2022 Q3	$36K	Hold	49,700	–	–	﹤0.01%	462
2022 Q2	$57K	Hold	49,700	–	–	﹤0.01%	470
2022 Q1	$102K	Hold	49,700	–	–	0.01%	500
2021 Q4	$143K	Hold	49,700	–	–	0.01%	296
2021 Q3	$211K	Hold	49,700	–	–	0.01%	272
2021 Q2	$263K	Hold	49,700	–	–	0.02%	260
2021 Q1	$231K	Hold	49,700	–	–	0.02%	257
2020 Q4	$164K	Hold	49,700	–	–	0.01%	274
2020 Q3	$165K	Sell	49,700 -392,404	-89%	-$1.44M	0.02%	220
2020 Q2	$1.49M	Buy	442,104 +39,892	+10%	+$189K	0.29%	40
2020 Q1	$1.54M	Hold	402,212	–	–	0.44%	31
2019 Q4	$2.43M	Hold	402,212	–	–	0.2%	96
2019 Q3	$3.04M	Sell	402,212 -9,000	-2%	-$101K	0.27%	76
2019 Q2	$5.57M	Buy	411,212 +387,512	+1,635%	+$4.47M	0.52%	34
2019 Q1	$128K	Hold	23,700	–	–	0.01%	553
2018 Q4	$70K	Hold	23,700	–	–	0.01%	524
2018 Q3	$193K	Buy	+23,700	New	+$182K	0.02%	607
2017 Q4	–	Sell	-13,600	Closed	-$114K	–	621
2017 Q3	$114K	Buy	+13,600	New	+$144K	0.02%	419

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Zeke Capital Advisors's ZYNE Position: Q4 2022 in Review

Zeke Capital Advisors held its Zynerba Pharmaceuticals, Inc (ZYNE) position steady in Q4 2022 at 49,700 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #468.

Zeke Capital Advisors first reported a position in ZYNE in Q3 2017 and has held it in 19 quarters since. The position peaked at $5.57M in Q2 2019. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

Zeke Capital Advisors held 49,700 shares of Zynerba Pharmaceuticals, Inc worth $26.3K as of Q4 2022.
Zeke Capital Advisors left its Zynerba Pharmaceuticals, Inc share count unchanged in Q4 2022.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #468 holding.
Zeke Capital Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and has held it in 19 quarters since.
Zeke Capital Advisors's Zynerba Pharmaceuticals, Inc position peaked at $5.57M in Q2 2019.
50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.